2025 年 7 月 12 日 总量研究 市场呈现反转风格，大宗交易组合超额收益显著 ——量化组合跟踪周报 20250712 要点 量化市场跟踪 大类因子表现：本周全市场股票池中，Beta 因子和估值因子分别获取正收益 0.48%、0.26%；市值因子和盈利因子分别获取负收益-0.24%、-0.42%，市场 表现为小市值风格；动量因子获取负收益-0.44%，市场表现为反转风格；其余 风格因子表现一般。 单因子表现：沪深 300 股票池中，本周表现较好的因子有单季度净利润同比增 长率 (1.83%)、单季度营业利润同比增长率 (1.75%)、净利润率 TTM (1.52%)。 表现较差的因子有早盘后收益因子(-1.76%)、动量弹簧因子 (-1.73%)、成交量 的 5 日指数移动平均 (-1.49%)。 中证 500 股票池中，本周表现较好的因子有市净率因子(2.57%)、下行波动率占 比 (2.07%)、市销率 TTM 倒数 (1.33%)。表现较差的因子有动量弹簧因子 (-1.23%)、单季度总资产毛利率(-1.22%)、总资产毛利率 TTM (-1.16%)。 流动性 1500 股票池中，本周表现较好的 ...

Core Insights - Demand for Eli Lilly's GLP-1 medicines, Mounjaro and Zepbound, remains robust, generating $6.15 billion in Q1 2025, accounting for approximately 48% of total revenues [1][8] - Sales of Mounjaro and Zepbound rebounded in Q1 2025 due to new international market launches and improved supply, despite lower-than-expected sales in the second half of 2024 [2][8] - The company anticipates Q2 2025 sales of $4.5 billion for Mounjaro and $3.1 billion for Zepbound, driven by deeper market penetration [3][8] Company Performance - Eli Lilly's broader portfolio, including oncology and immunology drugs, continues to show steady growth, with contributions from recently launched products [4] - The company's shares have outperformed the industry year-to-date, indicating strong market performance [7] Industry Context - The U.S. obesity market is projected to reach $100 billion by 2030, with Eli Lilly and Novo Nordisk as the primary competitors [5] - Novo Nordisk's semaglutide medicines, Ozempic and Wegovy, compete directly with Lilly's offerings, contributing significantly to Novo's revenues [5] - Other companies, such as Viking Therapeutics, are also advancing in the obesity space with new investigational drugs [6] Valuation and Estimates - Eli Lilly's shares are currently trading at a P/E ratio of 29.66, above the industry average of 15.16, but below its five-year mean of 34.54 [10] - The bottom-line estimate for 2025 remains at $21.92, while the estimate for 2026 has slightly decreased from $30.91 to $30.84 [11]

New additions bolster Hapbee as it scales product reach, tech pipeline, and international presence.VANCOUVER, British Columbia, July 11, 2025 (GLOBE NEWSWIRE) -- Hapbee Technologies, Inc. (TSXV: HAPB | OTCQB: HAPBF) (“Hapbee” or the “Company”), a leading wearable wellness technology company, is pleased to announce as an update to its press releases dated June 27, 2025 and September 26, 2024, the completion of the transformative changes to its Board of Directors which it began at its last AGM on June 12, 202 ...

大公司： 特斯拉在孟买开设的印度首个展厅下周开业，此前该公司已进口价值100万美元的汽车及周边商品，这 标志着特斯拉进军世界第三大汽车市场，尽管首席执行官马斯克抱怨印度进口关税高。特斯拉在周四晚 些时候向媒体发出的邀请函中表示，7月15日位于孟买核心商业区班德拉库尔拉综合体（Bandra Kurla Complex）的特斯拉体验中心开业，从而启动印度市场业务。（新浪财经） 绿地集团与深兰科技合资成立AI医疗公司 36氪获悉，近日，绿地集团与AI独角兽深兰科技合资成立"绿地深兰AI医疗科技公司"，核心目标是推动 冠军医疗大模型DeepBlue-MR-v1快速落地。该模型在权威评测MedBench中复杂医学推理排名第一，多 项综合评测夺冠。新公司将重点规模化推广该冠军医诊大模型产品；构建AI私人医生系统。 马蜂窝攻略定制产品"AI路书"正式向所有用户开放 36氪获悉，7月11日，马蜂窝的深度个性化的攻略定制产品"AI路书"正式宣布向所有用户开放，同步上 线"AI代订日本餐厅"、"菜单翻译"、"多语种实时翻译"等几大实用工具，实现从行程规划到目的地精细 化服务的全链路智能化覆盖。该产品突破传统AI被动响应模式，首创 ...

0% 5% 10% 15% 20% 25% 1/1 2/1 3/1 4/1 5/1 6/1 7/1 8/1 9/1 10/1 11/1 12/1 2021 2022 2023 2024 2025 铁矿石早报 研究中心黑色团队 2025/7/11 地区 品种 最新 日变化 周变化 折盘面 最新 日变化 周变化 进口利润 95.30 0.10 0.20 纽曼粉 743 22 29 794.3 96.05 2.95 2.40 -29.03 PB粉 748 23 25 792.1 98.30 2.85 2.25 -7.47 麦克粉 732 22 27 799.7 94.40 2.90 2.50 -4.47 金布巴 715 29 40 805.4 90.60 2.90 2.40 1.66 主流 混合粉 675 16 17 799.7 86.35 2.30 1.85 -2.30 超特粉 635 20 25 845.3 82.70 2.25 1.65 -5.34 卡粉 845 21 27 785.8 112.60 2.80 5.70 -25.14 巴西 巴混 782 23 25 794.1 101.50 3.40 3.00 ...

(活力中国调研行)从"机杼声声"到"黑灯工厂" 安康纺织上演智能"变形记" 由安康智港华纺织有限公司投资建设的汉阴县智能化高端纱线纺织产业园项目，占地70亩，计划总投资 6亿元，全面投产达效后，预计年产值超5亿元，占陕西省功能性纱线产能的三分之一以上，实现了由化 工原料到纺织产品的产业链闭环，并与安康现有服装、鞋袜、毛绒玩具等产业形成互补。 "PBT包芯纱线由PBT高弹丝与植物纤维包裹而成，在高端针织产品领域凭借出色染色效果和良好弹性 备受青睐。"陕西永丰特种纱线有限公司生产技术部主任孙志军介绍道。 7月11日，汉阴县智能化高端纱线纺织项目现场，工作人员检查产品。 李一璠 摄 中新网陕西安康7月11日电 (李一璠)"十五年前，我从家乡江苏张家港赴陕发展。拥有良好营商环境的安 康汉阴，吸引了众多深耕纺织行业的产业链上下游企业落户，并共同出资建设智能化高端纱线纺织产业 园，实现'企业迁移—产业扎根—集群发展'全周期协作图谱。"陕西永丰特种纱线有限公司董事长孙华 11日说。 纺织服装是安康市支柱产业之一，2024年，该市纺织服装产业实现产值24亿元，占全部规模以上工业产 值6%。当日，中新网记者跟随"活力中国调研行 ...

芯片超人现有 1600平米 芯片智能仓储基地，现货库存型号 1000+ ，品牌高达 100种 ， 5000万颗 现 货库存芯片，总重量 10吨 ，库存价值高达 1亿+ 。同时，芯片超人在深圳设有独立实验室，每颗物料 均 安排QC质检 。 求购以下料号 | 品牌 | 型号 | 数量 | | --- | --- | --- | | ADI | LTM4628EV#PBF | 200PCS | | ADI | AD8512ARMZ | 1200PCS | | DEGSON/高松 | 2EDGRM-5.08-03P-14-100Z(H) | 800PCS | 优势物料，特价出售 | 品牌 | 型号 | 数量 | 年份 | | --- | --- | --- | --- | | ADI | ADM2483BRWZ | 2K | 22+ | | ADI | ADRF5545ABCPZN-R7 | 30K | 22+ | | TI | TMS320F28027PTT | 7499pcs | 23+ | | WINBOND | W83627DHG | 876pcs | 21+ | | 润石 | RS2299XTQC16 | ...

Core Viewpoint - Eli Lilly and Company's stock has declined 15.7% over the past year due to a first-quarter earnings miss, guidance cut, and positive developments at rival Novo Nordisk, alongside broader economic challenges [1][10]. Group 1: Company Performance - Lilly's cardiometabolic division is its strongest segment, driven by the success of GLP-1 therapies Mounjaro and Zepbound, which together account for approximately 48% of total revenues [3][4]. - Despite slower-than-expected sales in the second half of 2024, Mounjaro and Zepbound saw a resurgence in the first quarter of 2025 due to new international market launches and improved supply [5][6]. - Lilly anticipates continued growth for Mounjaro and Zepbound through expanded international uptake and deeper market penetration in the U.S. [6][7]. Group 2: Product Pipeline and Future Growth - Lilly has secured approvals for several new therapies, including Omvoh, Jaypirca, Ebglyss, and Kisunla, which are expected to contribute to revenue growth in 2025 [10][11]. - The company is also advancing its pipeline in obesity, diabetes, and cancer, with several key mid and late-stage data readouts expected this year [12]. - Lilly is diversifying beyond GLP-1 drugs by expanding into cardiovascular, oncology, and neuroscience areas, including recent M&A deals to enhance its pipeline [13]. Group 3: Competitive Landscape - The obesity market is projected to reach $100 billion by 2030, with Lilly and Novo Nordisk currently dominating the space [14]. - Mounjaro and Zepbound face competition from Novo Nordisk's semaglutide products and emerging candidates from companies like Amgen and Viking Therapeutics [15][17]. - Other pharmaceutical companies are also entering the obesity market, which could challenge Lilly's and Novo Nordisk's market positions [18]. Group 4: Financial Outlook - Lilly expects 2025 revenues to be between $58 billion and $61 billion, indicating a year-over-year growth of approximately 32% [30]. - The company's stock has increased by over 400% in the past five years, primarily due to successful drug launches and a strong pipeline [29]. - Despite a high valuation with a price/earnings ratio of 29.54 compared to the industry average of 15.04, Lilly's stock is trading below its five-year mean [23].

PHILADELPHIA, July 10, 2025 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (“Passage Bio” or the “Company”) (NASDAQ: PASG), a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases, today announced that its Board of Directors (“Board”) has approved a reverse stock split of the company’s outstanding shares of common stock at a ratio of 1-for-20. The reverse stock split will become effective at 12:01 a.m. Eastern time on July 14, 2025. Passage Bio’s common s ...

| 品牌 | 型号 | 数量 | 年份 | | --- | --- | --- | --- | | DIODES | DMT10H009LCG-7 | 18K | 21+ | | LITTELFUSE | V320LA20AP | 60K | 22+ | | HYNIX | H5ANBG6NAMR-XNC | 40K | 22+ | | 润石 | RS2299XTQC16 | 100K | 24+ | 芯片超人现有 1600平米 芯片智能仓储基地，现货库存型号 1000+ ，品牌高达 100种 ， 5000万颗 现 货库存芯片，总重量 10吨 ，库存价值高达 1亿+ 。同时，芯片超人在深圳设有独立实验室，每颗物料 均 安排QC质检 。 求购以下料号 | 品牌 | 型号 | 数量 | | --- | --- | --- | | ADI | LTM4628EV#PBF | 200个 | | ADI | LTM4634IY#PBF | 238个 | | ADI | AD8512ARMZ | 1200个 | | DEGSON/高松 | 2EDGRM-5.08-03P-14-100Z(H) | 800PCS | 优势物 ...